$20.13+0.92 (+4.79%)
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects an...
What Alamar Biosciences stock is telling you right now Alamar Biosciences (ALMR) has attracted fresh attention after recent trading left the stock with a last close of US$23.01 and a year to date gain of 4.59%, against mixed shorter term returns. For context, the stock was roughly flat over the past day, gained 0.17%, but declined 3.48% over the past week. Month and past 3 months performance data is not available, so short term momentum beyond these windows is harder to compare. See our...
Toast downgraded, Lowe's upgraded: Wall Street's top analyst calls